Ausgabe 12/2016
Inhalt (11 Artikel)
The growing world of CAR T cell trials: a systematic review
Astrid Holzinger, Markus Barden, Hinrich Abken
Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer
Mariëtte I. E. van Poelgeest, Valeria V. Visconti, Zohara Aghai, Vanessa J. van Ham, Moniek Heusinkveld, Maarten L. Zandvliet, A. Rob P. M. Valentijn, Renske Goedemans, Caroline E. van der Minne, Els M. E. Verdegaal, J. Baptist M. Z. Trimbos, Sjoerd H. van der Burg, Marij J. P. Welters
Macrophage migration inhibitory factor (MIF) is induced by cytotoxic drugs and is involved in immune escape and migration in childhood rhabdomyosarcoma
Sarah Maria Johler, Jörg Fuchs, Guido Seitz, Sorin Armeanu-Ebinger
Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
Toshiko Kamata, Akane Suzuki, Naoko Mise, Fumie Ihara, Mariko Takami, Yuji Makita, Atsushi Horinaka, Kazuaki Harada, Naoki Kunii, Shigetoshi Yoshida, Ichiro Yoshino, Toshinori Nakayama, Shinichiro Motohashi
Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model
Lydia Dyck, Mieszko M. Wilk, Mathilde Raverdeau, Alicja Misiak, Louis Boon, Kingston H. G. Mills
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma
Yasuharu Akasaki, Tetsuro Kikuchi, Sadamu Homma, Shigeo Koido, Toshifumi Ohkusa, Tetsunori Tasaki, Kazumi Hayashi, Hideo Komita, Nobuyuki Watanabe, Yuta Suzuki, Yohei Yamamoto, Ryosuke Mori, Takao Arai, Toshihide Tanaka, Tatsuhiro Joki, Takaaki Yanagisawa, Yuichi Murayama
Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models
Emily A. Lanzel, M. Paula Gomez Hernandez, Amber M. Bates, Christopher N. Treinen, Emily E. Starman, Carol L. Fischer, Deepak Parashar, Janet M. Guthmiller, Georgia K. Johnson, Taher Abbasi, Shireen Vali, Kim A. Brogden
Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2
Wei Wang, Amy K. Erbe, Mikayla Gallenberger, KyungMann Kim, Lakeesha Carmichael, Dustin Hess, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Su-Chun Cheng, Sabina Signoretti, Michael Atkins, Alexander Carlson, Jonathan M. Weiss, James Mier, David Panka, David F. McDermott, Paul M. Sondel
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
Ajjai Alva, Gregory A. Daniels, Michael K. K. Wong, Howard L. Kaufman, Michael A. Morse, David F. McDermott, Joseph I. Clark, Sanjiv S. Agarwala, Gerald Miletello, Theodore F. Logan, Ralph J. Hauke, Brendan Curti, John M. Kirkwood, Rene Gonzalez, Asim Amin, Mayer Fishman, Neeraj Agarwal, James N. Lowder, Hong Hua, Sandra Aung, Janice P. Dutcher
Surface biotinylation of cytotoxic T lymphocytes for in vivo tracking of tumor immunotherapy in murine models
Anning Li, Yue Wu, Jenny Linnoila, Benjamin Pulli, Cuihua Wang, Matthias Zeller, Muhammad Ali, Grant K. Lewandrowski, Jinghui Li, Benoit Tricot, Edmund Keliher, Gregory R. Wojtkiewicz, Giulia Fulci, Xiaoyuan Feng, Bakhos A. Tannous, Zhenwei Yao, John W. Chen
Anti-GITR therapy promotes immunity against malignant glioma in a murine model
Jason Miska, Aida Rashidi, Alan L. Chang, Megan E. Muroski, Yu Han, Lingjiao Zhang, Maciej S. Lesniak